Literature DB >> 11823046

Somatostatin is a selective chemoattractant for primitive (CD34(+)) hematopoietic progenitor cells.

Sigrid P M A Oomen1, Paula B van Hennik, Claudia Antonissen, Elgin G R Lichtenauer-Kaligis, Leo J Hofland, Steven W J Lamberts, Bob Löwenberg, Ivo P Touw.   

Abstract

OBJECTIVE: Somatostatin (SST) is a regulatory peptide with a wide variety of activities in different tissues. SST activates G(alpha i)-protein-coupled receptors of a family comprising five members (SSTR1-5). Despite the broad use of SST and its analogs in clinical practice, the spectrum of activities of SST is incompletely defined. Here, we examined the role of SST and its receptors in hematopoiesis.
MATERIALS AND METHODS: SSTR expression on human and mouse hematopoietic cells was analyzed by flow cytometry and reverse transcriptase polymerase chain reaction. The effects of SST on cell migration were measured in transwell assays. Using selective inhibitors, signaling mechanisms involved in SSTR2-mediated migration were studied in 32D cell transfectants expressing SSTR2.
RESULTS: Human hematopoietic cells exclusively expressed SSTR2, whereas mouse bone marrow cells expressed SSTR2 and SSTR4. SSTR levels were high on primitive (CD34(+), Lin(-)) but low or absent on more mature (CD34(-), Lin(+)) cell types. Both SST and its analog octreotide acted as chemoattractants for primitive hematopoietic cells. Despite the presence of SSTR4, bone marrow cells from SSTR2-deficient mice failed to migrate toward SST gradients, suggesting that SSTR2 and SSTR4 are functionally different in this respect. SST activated phosphatidylinositol 3-kinase and the MAP kinases Erk1/2 and p38 in 32D[SSTR2] cells. While chemical inhibitors of these kinases had some effect, SST-induced migration was most strongly affected by blocking G(alpha i) activity or by elevating intracellular cAMP levels.
CONCLUSIONS: Somatostatin acts as a selective chemoattractant for immature hematopoietic cells via activation of multiple intracellular pathways.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823046     DOI: 10.1016/s0301-472x(01)00772-x

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

1.  Mechanisms underlying modulation of monocarboxylate transporter 1 (MCT1) by somatostatin in human intestinal epithelial cells.

Authors:  Seema Saksena; Saritha Theegala; Nikhil Bansal; Ravinder K Gill; Sangeeta Tyagi; Waddah A Alrefai; Krishnamurthy Ramaswamy; Pradeep K Dudeja
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11       Impact factor: 4.052

2.  Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts.

Authors:  Stephan Walrand; Raffaella Barone; Stanislas Pauwels; François Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-12       Impact factor: 9.236

Review 3.  Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data.

Authors:  Gabriele Zoppoli; Federico Bianchi; Andrea Bruzzone; Alessandro Calvia; Caterina Oneto; Caterina Passalia; Enrico Balleari; Davide Bedognetti; Elena Ponomareva; Elena Nazzari; Lara Castelletti; Lucio Castellan; Francesco Minuto; Riccardo Ghio; Diego Ferone
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

4.  Somatostatin stimulates the migration of hepatic oval cells in the injured rat liver.

Authors:  Youngmi Jung; Seh-Hoon Oh; Rafal P Witek; Bryon E Petersen
Journal:  Liver Int       Date:  2011-09-14       Impact factor: 5.828

5.  Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells.

Authors:  Polina Zjablovskaja; Petr Danek; Miroslava Kardosova; Meritxell Alberich-Jorda
Journal:  J Vis Exp       Date:  2018-02-21       Impact factor: 1.355

6.  Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells.

Authors:  Vassilis Valatas; George Kolios; Pinelopi Manousou; George Notas; Costas Xidakis; Ioannis Diamantis; Elias Kouroumalis
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

7.  Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.

Authors:  Flavio Forrer; Eric P Krenning; Peter P Kooij; Bert F Bernard; Mark Konijnenberg; Willem H Bakker; Jaap J M Teunissen; Marion de Jong; Kirsten van Lom; Wouter W de Herder; Dik J Kwekkeboom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-27       Impact factor: 9.236

Review 8.  Advances in Instrumental Analysis of Brominated Flame Retardants: Current Status and Future Perspectives.

Authors:  Mohamed Abou-Elwafa Abdallah
Journal:  Int Sch Res Notices       Date:  2014-10-28

9.  Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target.

Authors:  Saman Sizdahkhani; Michael J Feldman; Martin G Piazza; Alexander Ksendzovsky; Nancy A Edwards; Abhik Ray-Chaudhury; Dragan Maric; Marsha J Merrill; Karel Pacak; Zhengping Zhuang; Prashant Chittiboina
Journal:  Sci Rep       Date:  2017-01-17       Impact factor: 4.379

10.  Combination therapies prevent the neuropathic, proinflammatory characteristics of bone marrow in streptozotocin-induced diabetic rats.

Authors:  James M Dominguez; Mark A Yorek; Maria B Grant
Journal:  Diabetes       Date:  2014-09-09       Impact factor: 9.461

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.